Drug Database
BE

beclometasone dipropionate (Aerobec / Junik / Ventolair)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule

What is beclometasone dipropionate?

beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesAerobec, Junik, Ventolair
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

beclometasone dipropionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

beclometasone dipropionate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

Related Research Articles

PubMedPathogens (Basel, Switzerland)2026-08-27

Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected with Babesia aktasi.

Ulucesme Mehmet Can MC, Ozubek Sezayi S, Aktas Munir M

Babesia aktasi is a recently discovered species that is highly prevalent in native goats in Türkiye's Mediterranean region. Although it does not induce clinical disease in local breeds, it causes severe illness in Saanen goats, manifesting with high fever, anemia, hemoglobinuria, and jaundice. Imidocarb dipropionate (IMDP) has been reported to be therapeutically effective against Babesia species. This study aimed to evaluate the therapeutic efficacy of IMDP and its ability to eliminate the parasite in experimentally infected Saanen goats. Twelve goats were assigned to treatment and control groups (n = 5 per group) and infected using fresh blood from two splenectomized donors. All goats developed clinical babesiosis, with parasitemia ranging from 3.8% to 22. Semi-nested PCR specific to B. aktasi was performed for 30 days post-treatment. Following treatment with IMDP (1.2 mg/kg), clinical signs resolved by the third and fourth days, and parasitemia became microscopically undetectable. However, one goat in the treatment group and four goats in the control group died shortly after infection. Hematological parameters (HCT, RBC, HB) decreased during infection but normalized in surviving animals. Notably, B. aktasi DNA remained detectable by PCR up to 30 days after treatment. These findings indicated that IMDP resolved clinical signs and eliminated microscopically detectable parasitemia; however, it may not completely eliminate the parasite at the molecular level in B. aktasi infections. The results of this study provide valuable information for optimizing therapeutic approaches and improving our understanding of treatment responses in new species B. aktasi.

PMID 42654770
Read full article →
PubMedVeterinary medicine and science2026-08-27

Clinical Case and Follow-Up of Babesia banethi Infection in a Red Fox.

Carbonara Mariaelisa M, Prioletti Michela M, Camarda Antonio A, Castellana Stefano S et al.

Red foxes play an important role in the circulation of ticks and tick-borne pathogens, including Babesia spp. While for Babesia vulpes many studies are available on its epidemiology in fox populations as well as pathogenicity in dogs, no data are reported for the recently described Babesia banethi infecting red foxes. Here we describe the clinical and parasitological follow-up of a naturally occurring B. banethi infection in a red fox from southern Italy. An adult male fox presented with severe debilitation, weight loss, pale mucous membranes, brown discolouration of urine and sarcoptic mange. Haematological examination revealed regenerative anaemia associated with left-shift neutrophilia and lymphocytosis. Blood smear examination showed intraerythrocytic inclusions morphologically consistent with small piroplasmids, and PCR amplification and sequencing of the 18S rDNA gene confirmed infection with B. banethi. Screening for other vector-borne pathogens scored negative. Treatment with imidocarb dipropionate resulted in temporary clinical and haematological improvement but persistence of PCR positivity and later relapse of parasitaemia and clinical signs. Subsequently, treatment with atovaquone/proguanil combined with azithromycin led to marked clinical recovery and disappearance of parasites at blood smear examination, although PCR positivity persisted for several months. A second therapeutic course resulted in both cytological and molecular negativity. This longitudinal case report provides the first detailed account of the clinical course, therapeutic response and long-term parasitological follow-up of B. banethi infection in a red fox, suggesting that this piroplasm might cause clinically relevant and persistent infection, yet further validation of this hypothesis on a larger number of clinical cases is advocated. Not applicable.

PMID 42656136
Read full article →
PubMedItalian journal of dermatology and venereology2026-08-24

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.

Gisondi Paolo P, Burlando Martina M, Esposito Maria M, Megna Matteo M et al.

The fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BDP) is an established topical psoriasis treatment. The cream formulation of Cal/BDP has been found effective and well-tolerated for the treatment of mild-to-moderate disease, with high levels of patient satisfaction. The aim of this consensus document is to guide optimal real-life use of Cal/BDP cream in patients with psoriasis. Eight hospital-based dermatologists, with long-standing experience in psoriasis treatment, developed a consensus document on three topics (therapeutic protocols and schedules; high-impact areas; and treatment adherence) regarding the use of Cal/BDP cream in clinical practice. A modified Delphi process was used to achieve consensus among panel members. Statements with treatment recommendations, based on the experts' opinions and experience, as well as an analysis of relevant published data, were elaborated on and discussed during two meetings occurring two months apart. Full agreement among panel members was obtained after two online Delphi rounds. As seen in clinical trials, Cal/BDP cream monotherapy has proved beneficial in the treatment of mild to moderate plaque psoriasis. However, it can also be used as an adjunct to systemic/biologic drug treatment or as long-term maintenance therapy. Cal/BDP cream also plays an important role in the treatment of psoriasis on high-impact sites (including the scalp, peripheral facial areas, skin folds and palmoplantar areas) with treatment schedules varying according to disease severity and area involved. Due to its vehicle, treatment with Cal/BDP cream is associated with high levels of treatment convenience and patient acceptability, positively impacting adherence. Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed.

PMID 42634951
Read full article →
PubMedOrthopedic research and reviews2026-08-12

Effect Of Intraarticular Triamcinolone Hexacetonide versus Betamethasone on Intraocular Pressure: A Prospective Randomized Study.

Yağar Hilal H, Biçer Kadir Eren KE, Yıldırım Biçer Gamze G

Corticosteroids may cause glaucoma by increasing intraocular pressure (IOP) due to their systemic side effects. Few studies have investigated the effect of intraarticular corticosteroids (IACS) on IOP. This study aimed to evaluate the effects of IACS preparations (betamethasone and triamcinolone hexacetonide) on IOP. In this single-center randomized study, patients receiving IACS were randomized into two groups: Group 1 received betamethasone (Diprospan®, betamethasone dipropionate 6.43 mg + betamethasone sodium phosphate 2.63 mg, equivalent to 7.0 mg betamethasone) and Group 2 received triamcinolone hexacetonide (Artropan®,20 mg triamcinolone hexacetonide). IOP was measured before injection and at 1 week after injection. The change in IOP (ΔIOP) was calculated using the following formula: IOP (after injection) - IOP (before injection). A total of 80 patients and 160 eyes were included in the study, with 40 patients in each group. No significant change was found in ΔIOP in Group 1 (p > 0.05). A statistically significant increase in ΔIOP was observed in both eyes and in the left eye in Group 2; (both eyes: p = 0.002; left eye: p = 0.012; right eye:p = 0.060). ΔIOP was significantly higher in Group 2 than in Group 1 (p = 0.043). Triamcinolone hexacetonide may increase IOP after IACS more than betamethasone; caution is warranted in patients with risk factors for glaucoma. The trial was registered at ClinicalTrials.gov retrospectively (No: NCT07242846, Date: 17.11.2025).

PMID 42583198
Read full article →
PubMedTierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere2026-08-12

Clinicopathological abnormalities, treatment, and outcome in in a 45-day-old puppy with acute Babesia canis infection.

Schäfer Ingo I, Stüwe Sophia S, Fürst Kathrin K, Strube Christina C et al.

The knowledge regarding Babesia canis infections in puppies is limited to 3 dogs aged 43-46 days. A 45-day-old, male intact German Shepherd dog was presented due to lethargy, inappetence, and gait disorders. An acute Babesia canis infection was diagnosed by PCR. Marked thrombocytopenia, anemia, and hyperbilirubinemia were noted. A subcutaneous injection of imidocarb dipropionate (ID, 2.0 mg/kg bodyweight) was applied. The puppy's general condition significantly improved, but vomitus was noted. A negative PCR and mild hematological abnormalities were seen 14 days later. A second subcutaneous injection of ID (4.2 mg/kg bodyweight) was applied. Babesia canis infections should be considered in puppies with fever, marked thrombocytopenia, and marked anemia in the immunological gap. Next to vectorial transmission, transplacental Babesia canis infections are reported but considered unlikely in the presented puppy. The puppy responded well to a lower-ranged dose of ID, but side effects were noted (vomiting). In adult dogs, treatment of acute Babesia canis infections using ID dosed 6.6 mg/kg bodyweight is recommended. No safety regulations are published by the manufacturer regarding the use of ID in puppies, but vomitus is reported as a potential side effect after the use in adult dogs. A second ID injection (4.2 mg/kg bodyweight) was applied to avoid a potential disease relapse. The case report highlights the significance of the immunological gap in puppies with Babesia canis infections and the need for ectoparasite prophylaxis in puppies, if vector contact is possible.

PMID 42586170
Read full article →
PubMedDermatology and therapy2026-08-10

Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.

Bewley Anthony A, Pinter Andreas A, López Estebaranz José Luis JL, Galván Jordi J et al.

Scalp psoriasis is often associated with poor adherence to topical therapy. A novel formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion (CAL/BDP PAD-cream) showed improved outcomes and satisfaction in the PRO-SCALP study, particularly in patients with high adherence. We evaluated how adherence to CAL/BDP PAD-cream influences patients- and clinicians-reported outcomes and treatment preferences in mild-to-moderate scalp psoriasis under real-life conditions in Europe. PRO-SCALP patients reported their adherence level using a visual analogue scale (VAS). Outcomes were compared between low- and high-adherence subgroups. Among 252 patients, 59.9% reported high adherence (VAS 80-100). Older patients and those with moderate disease reported high adherence (both p < 0.05). High-adherent patients reported higher scores in the Treatment Satisfaction Questionnaire for Medication Version 9, for Convenience of use (p = 0.0019) and Global Satisfaction (p = 0.0166) domains, and in the Psychosocial Effects of Scalp Psoriasis Questionnaire (p = 0.0004) at week 8. Both adherence subgroups showed significant reductions in the scalp Worst Itch Numeric Rating Scale (WI-NRS), scalp-modified Psoriasis Area and Severity Index (S-mPASI), and Scalpdex scores (all p < 0.0001 vs. baseline), although high-adherent patients achieved greater improvements in WI-NRS (p < 0.0001), S-mPASI (p = 0.0153), and the Scalpdex Symptoms domain (p = 0.001) than low-adherent. Each 10% increase in adherence corresponded to a 0.10- and 0.35-point reduction in S-mPASI and WI-NRS (both p < 0.05) at week 8. Scalp-Physician Global Assessment success rates were comparable in low- vs. high-adherence subgroups (65.0% vs. 70.5%; p = 0.3633). Sleep quality improved significantly in both subgroups (p < 0.0001). High adherence was associated with higher Patient Preference Questionnaire scores (p = 0.0012), better Cream Usability Scalp Psoriasis Questionnaire ratings (p = 0.0455) and greater product consumption (p < 0.0001), despite similar once-a-day usage. High adherence to CAL/BDP PAD-cream was associated with greater effectiveness, satisfaction, preference, and QoL. While patients with low adherence still benefited, maximizing adherence is key for optimal real-world outcomes in scalp psoriasis. ClinicalTrials.gov identifier NCT05811234.

PMID 42573965
Read full article →

+3751 more articles available with a free account

Sign up free to view all articles →

Ask about beclometasone dipropionate